Results 61 to 70 of about 14,264 (186)
Glargine and glycemia: Pitfalls and perils [PDF]
, 2012 invited, 6-pagesAbstract: Type 1 diabetics exhibit an unfulfilled basal insulin requirement, currently treated with long-acting subcutaneous insulins such as glargine. Due to glagine’s unique flat peak the drug is an ideal basal insulin replacement.
Fisk, L. +4 more
core +1 more source
Long‐term survival after surgical removal of an intermediate grade pancreatic carcinoma in a cat
Veterinary Record Case Reports, Volume 14, Issue 4, November 2026.Abstract An 11‐year‐old male neutered domestic shorthair cat presented with a history of acute diarrhoea, decreased appetite, and a palpable abdominal mass. Following clinical staging and histopathological examination after partial pancreatectomy, the cat was diagnosed with a completely excised intermediate grade pancreatic carcinoma without evidence ...
Abel Verbrugghe +4 more
wiley +1 more source
Bioinformatics and Biology Insights, 2021 Introduction: Insulin and insulin-like growth factor type 1 (IGF1) regulate multiple physiological functions by acting on the insulin receptor (IR) and insulin-like growth factor type 1 receptor (IGF1R).
Margarita González-Beltrán +1 more
doaj +1 more source
Journal of Institute of Medicine Nepal, 2008 Abstract: Insulin glargine is a long-acting human insulin analog prepared using recombinant DNA technology. It is the first long-acting analog of human insulin to be approved for clinical use. It is administered once daily and has a smooth 24 hour time-action profile that provides effective glycemic control with minimal risk of hypoglycemia.
D.K. Upadhayay +4 more
openaire +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10725-10735, November 2026.ABSTRACT Aims To conduct indirect treatment comparisons (ITCs) of insulin efsitora alfa (efsitora) versus insulin icodec (icodec) in insulin‐experienced individuals with Type 2 Diabetes Mellitus. Methods Efficacy, safety and patient reported outcomes were compared via matching‐adjusted ITCs using results from randomised controlled trials: QWINT‐3 ...
Harpreet S. Bajaj +8 more
wiley +1 more source
Low Weight Loss Response to Incretin Analogs: A Systematic Review
Obesity Reviews, Volume 27, Issue 11, November 2026.ABSTRACT The development of GLP‐1 and GIP analogs has been a significant breakthrough in type 2 diabetes and obesity pharmacotherapy. However, individual responses to these medications can vary widely. This systematic review examines factors associated with low or no weight loss response to GLP‐1 and GIP analogs. Key predictors of poor response include
Pamela S. Gaskin, Peter S. Chami
wiley +1 more source
The economic prognosis of the new analog of insulin glargine usage in diabetes mellitus type 2
Качественная клиническая практика, 2018 Modelling has been performed for evaluation of economic perspectives of new insulin glargine 300 IU/ml usage for diabetes mellitus type 2 (DM2) control based on literature analysis of non-direct comparison with insulin detemir.
D. Yu. Belousov, E. V. Afanasyeva
doaj
Clinical Case Reports, Volume 14, Issue 10, October 2026.ABSTRACT Dorsal pancreatic agenesis (DPA) is a rare congenital disorder resulting from failure of development of the dorsal pancreatic bud. Complete DPA implies absence of the pancreatic neck, body, and tail and can be associated with both diabetes mellitus and pancreatitis. The patient was an 18‐year‐old man admitted with a history of epigastric pain,
Mugheesa Rab +5 more
wiley +1 more source
Clinical Case Reports, Volume 14, Issue 10, October 2026.ABSTRACT A 42‐year‐old antibiotic‐naïve man with previous laparoscopic cholecystectomy and poorly controlled type 2 diabetes mellitus (HbA1c 9.7%) presented with Charcot's triad 7 days after a formally documented normal hepatobiliary evaluation (alanine aminotransferase [ALT] 22 U/L; total bilirubin 0.7 mg/dL [12 μmol/L]; common bile duct [CBD] ≤ 5 mm ...
Hatem Mousa Taha, Khaled Hatem Taha
wiley +1 more source
, 2011 Shinya Abe1,2, Gaku Inoue1,2, Satoru Yamada1,3, Junichiro Irie1,3, Hiroyuki Nojima2, Kaoru Tsuyusaki2, Kensuke Usui2, Koichiro Atsuda2, Toshikazu Yamanouchi41Diabetes Center, Kitasato Institute Hospital, 2Center for Clinical Pharmacy and Clinical ...
Atsuda K +8 more
core